Three separate papers on the kidney drug finerenone landed in the New England Journal of Medicine, The Lancet, and JAMA on the same day, each reporting that the drug met its primary endpoints. The coordinated publication package is the first time finerenone has shown kidney-protective benefits in patients with chronic kidney disease who do not have diabetes, a population that until now lacked an approved mineralocorticoid receptor antagonist targeting kidney decline. Together, the studies span non-diabetic CKD, a pooled diabetic and non-diabetic population, and a focused look at glomerular diseases, creating the broadest evidence base the drug has produced to date.
Why simultaneous publication across three journals changes the calculus
Finerenone was already approved for adults with type 2 diabetes and CKD based on two earlier Phase 3 trials, FIDELIO-DKD and FIGARO-DKD. Those studies established that the drug slowed kidney function loss and reduced cardiovascular events in diabetic patients. A pooled analysis of those two trials, known as FIDELITY, reinforced the findings but left a critical gap: no randomized evidence existed for the millions of CKD patients whose disease is not driven by diabetes.
The new FIND-CKD trial directly addresses that gap. Registered under the identifier NCT05047263, the study enrolled adults with non-diabetic CKD caused by glomerular disorders and measured whether finerenone could slow the rate at which their kidneys lost filtering capacity, quantified as the slope of estimated glomerular filtration rate, or eGFR. Hitting that eGFR-slope endpoint is significant because a steeper decline in eGFR is the clearest predictor of eventual kidney failure and the need for dialysis or transplant.
The practical question is whether slowing eGFR decline in a clinical trial will translate into fewer patients reaching dialysis chairs in everyday practice. If the consistent benefit holds when non-diabetic patients are added to the broader CKD population already studied, real-world registries tracking finerenone prescriptions should show measurable delays in dialysis initiation within the next several years. That hypothesis cannot be confirmed by trial data alone, but the signal is strong enough to reshape how nephrologists and regulators think about the drug’s role.
FIND-CKD, INFINITY, and the JAMA glomerular analysis in detail
The FIND-CKD outcomes report is the anchor of the three-journal package. As a primary Phase 3 trial in adults with non-diabetic CKD due to glomerular disorders, it was designed to stand on its own as a registration-quality study. The trial met its primary eGFR-slope endpoint, and hyperkalemia rates, the main safety concern with mineralocorticoid receptor antagonists, remained consistent with what earlier finerenone trials had reported. Importantly, the benefit appeared on top of contemporary background therapy, including renin–angiotensin system blockers and, where appropriate, sodium-glucose cotransporter 2 inhibitors.
The second paper, published in The Lancet as the INFINITY analysis, took a different approach. Rather than testing a new hypothesis in a new population, INFINITY combined individual-participant data from FIND-CKD with the two earlier diabetic-CKD trials, FIDELIO-DKD and FIGARO-DKD. This prespecified pooled analysis allowed researchers to estimate finerenone’s effect across the full spectrum of CKD, with and without diabetes, using the most granular patient-level data available. The cross-population design strengthens the case that finerenone’s kidney benefits are not limited to a single disease mechanism and suggests that mineralocorticoid receptor overactivation may be a common downstream pathway in diverse kidney injuries.
The third paper, a randomized clinical trial published in JAMA, zeroed in on patients with CKD specifically caused by glomerular diseases. This subset analysis complements FIND-CKD by isolating the disease category where proteinuria tends to be highest and kidney decline fastest. In that setting, even modest relative risk reductions can translate into substantial absolute gains, because baseline risk of progression is so high. By publishing all three papers simultaneously, the research teams ensured that clinicians and regulators could evaluate the full evidence package at once rather than waiting months between publications.
Finerenone’s evidence base now extends beyond the kidney. The FINEARTS-HF trial, a separate study in patients with heart failure with mildly reduced or preserved ejection fraction, tested the same drug in a cardiovascular context and was also published in the New England Journal of Medicine. While that trial is not part of the kidney-focused package, it reinforces the broader cardio-renal profile that distinguishes finerenone from older mineralocorticoid receptor antagonists like spironolactone and eplerenone, which have historically been limited by higher rates of hyperkalemia and endocrine side effects.
What the data could mean for guidelines and regulators
For guideline committees, the three-journal release provides a coherent narrative: finerenone now has randomized evidence in diabetic CKD, non-diabetic CKD, and mixed pooled populations, with consistent signals on kidney outcomes and acceptable safety. That breadth makes it easier to recommend the drug not as a niche therapy but as a potential foundation stone of CKD management alongside renin–angiotensin system blockade and SGLT2 inhibition, particularly for patients with persistent albuminuria.
Regulators reviewing label expansions will focus on whether the FIND-CKD results are robust enough on their own to justify approval in non-diabetic CKD, or whether they should be interpreted mainly through the lens of the INFINITY pooled analysis. Because FIND-CKD was designed as a registration-quality trial with a prespecified primary endpoint and clear statistical hierarchy, it provides a straightforward basis for regulatory decision-making. INFINITY, in turn, offers supportive evidence that the magnitude of benefit in non-diabetic disease is broadly aligned with what has already been seen in diabetes-driven CKD.
Health technology assessment bodies and payers will ask a different question: how many dialysis starts, transplants, and hospitalizations can be avoided per 1,000 patients treated, and at what cost? The eGFR-slope data give a mechanistic rationale for benefit, but reimbursement decisions will likely hinge on longer-term follow-up, including hard endpoints such as sustained eGFR decline, kidney failure, and cardiovascular events. Until those data mature, some systems may restrict coverage to patients at highest risk of progression, such as those with heavy proteinuria or rapidly falling eGFR despite optimized standard therapy.
Open questions after the three-trial kidney package
The published papers report efficacy and safety within the controlled conditions of randomized trials, but several gaps remain. None of the three publications includes patient-level raw datasets or individual site-level outcomes that would allow independent verification of the aggregate results. Without such transparency, external investigators cannot easily probe for heterogeneity across centers, adherence patterns, or subtle imbalances in concomitant medications that might influence outcomes.
Cost, pricing, and reimbursement data tied to a potential non-diabetic CKD indication are also missing from the clinical reports. For many health systems, the key issue will be how to prioritize finerenone relative to other disease-modifying therapies in an era of constrained budgets. If payers choose to sequence drugs rather than use them in combination, patients may not receive the full benefit suggested by the trial regimens, which layered finerenone on top of standard-of-care agents.
Another unresolved area is how best to monitor and manage hyperkalemia risk outside trial settings. In FIND-CKD and the related analyses, potassium elevations were generally manageable with dose adjustments and temporary interruptions, but real-world practice may not mirror the intensive laboratory surveillance of a Phase 3 program. Clear protocols for potassium monitoring, dietary counseling, and use of potassium binders will be essential if finerenone is to be deployed widely in community nephrology clinics.
Finally, questions remain about which patient subgroups stand to benefit most. The pooled INFINITY dataset suggests broadly consistent relative effects across diabetic and non-diabetic etiologies, but absolute risk reductions will depend on baseline progression rates. Patients with slowly progressive disease may see smaller absolute gains, raising the possibility that individualized risk calculators will be needed to guide prescribing decisions. As longer-term follow-up and real-world data accumulate, clinicians will be watching to see whether the early eGFR-slope advantages translate into durable protection against kidney failure and cardiovascular events across the full spectrum of CKD.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
